Kazia has launched a new Scientific Advisory Board (SAB) consisting of four distinguished clinicians and scientists with expertise in the development of innovative therapies for brain cancer.
The new SAB will guide Kazia as it advances paxalisib toward the completion of the GBM AGILE trial in the second half of next year – a pivotal study in glioblastoma which began recruiting early last year – and potential commercialisation to follow.
Read more here.
